Abstract

An update on bioresorbable vascular scaffolds: from lesion preparation, deployment and beyond

Author(s): JR Costa Jr & A Abizaid

Percutaneous balloon aortic valvuloplasty (PBAV) was first described as a new therapeutic option in patients with aortic stenosis who could not undergo surgical aortic valve replacement (SAVR) in a pediatric population in 1984 by Lababidi, and in elderly adults in 1986 by Cribier et al. This treatment was found to be an interesting option in high-risk patients with hemodynamic instability, showing good procedural and short-term results, yielding improvement of symptoms, amelioration of global clinical status and improvement of echocardiographic parameters.